First Case of High-Level Azithromycin-Resistant Neisseria gonorrhoeae in North Carolina

Sex Transm Dis. 2020 May;47(5):326-328. doi: 10.1097/OLQ.0000000000001149.

Abstract

We report on the first high-level azithromycin-resistant Neisseria gonorrhoeae isolate (minimum inhibitory concentration, ≥256 μg/mL) in North Carolina isolated from a pharyngeal swab of a 33-year-old HIV-negative man who has sex with men. In addition, the isolate was found to be susceptible to cefixime, ceftriaxone, and penicillin and resistant to tetracycline. By whole-genome sequencing, the strain was assigned as MLST ST9363, NG-MAST ST5035, and a novel NG-STAR sequence type, ST1993.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Azithromycin / pharmacology*
  • Azithromycin / therapeutic use
  • Cefixime / pharmacology
  • Cefixime / therapeutic use
  • Ceftriaxone / pharmacology
  • Ceftriaxone / therapeutic use
  • Drug Resistance, Bacterial / drug effects
  • Drug Resistance, Bacterial / genetics
  • Gonorrhea / drug therapy*
  • HIV Seronegativity
  • Homosexuality, Male
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Multilocus Sequence Typing
  • Neisseria gonorrhoeae / drug effects*
  • Neisseria gonorrhoeae / genetics
  • North Carolina / epidemiology
  • Penicillins / pharmacology
  • Penicillins / therapeutic use
  • Pharynx / microbiology
  • Tetracycline / pharmacology
  • Tetracycline / therapeutic use
  • Whole Genome Sequencing

Substances

  • Anti-Bacterial Agents
  • Penicillins
  • Ceftriaxone
  • Azithromycin
  • Cefixime
  • Tetracycline